LL-37: A Research Overview

LL-37 is the human body’s own broad-spectrum antimicrobial peptide — a frontline component of innate immunity — and a molecule of intense research interest precisely because it does more than kill microbes. It also shapes immune responses, influences blood vessel formation, and behaves differently across cellular contexts. That context-dependence is the honest center of the LL-37 story: it is not a simple “antimicrobial,” and its biology can cut both ways. This overview describes that nuanced picture and keeps the compound’s preclinical, research-only status clear.

This overview summarizes what the published literature reports about LL-37 — its identity, mechanisms, the double-edged biology, evidence, and status. It describes findings as they appeared in their study systems. It is not dosing guidance, medical advice, or a recommendation for use.

What LL-37 Is

LL-37 is a human antimicrobial peptide of the cathelicidin family, consisting of 37 amino acids (its name reflects two leading leucines and its length). It is produced predominantly by neutrophils and epithelial cells, cleaved from the precursor protein hCAP-18 (human cationic antimicrobial protein, 18 kDa) (LL-37 identity, cathelicidin family, hCAP-18 origin). It is cationic (positively charged), which underlies its interactions with microbial membranes.

Mechanism — Antimicrobial and Beyond

LL-37’s primary defining activity is direct, broad-spectrum bactericidal action: its cationic, amphipathic structure enables it to disrupt negatively charged microbial membranes. But a large part of why it draws research attention is its second life as an immunomodulator: LL-37 binds host receptors (including chemokine and growth-factor receptors) and orchestrates immune responses in leukocytes and epithelial cells, and it acts on endothelial cells — inducing angiogenesis via formyl peptide receptor 2 (FPR2) (antimicrobial + immunomodulatory + angiogenic mechanisms). So it is simultaneously an antibiotic-like agent and a signaling molecule.

The Double-Edged Biology — An Honest Caveat

LL-37 is not uniformly “beneficial,” and responsible framing has to say so. Its effects are context-dependent: for example, in senescent (aged) endothelial cells, LL-37 has been shown to more potently activate pro-inflammatory NF-κB p65 signaling and ICAM-1 expression than in non-senescent cells — work discussed in the context of atherosclerosis (context-dependent pro-inflammatory effect in senescent endothelium). LL-37 has also been implicated in certain inflammatory and autoimmune conditions in the broader literature. The accurate picture is that a host peptide is a powerful, multifunctional agent whose actions depend heavily on cell type and context — helpful in some settings, potentially pro-inflammatory in others — not a one-directional therapeutic.

The Evidence Base

LL-37 is well characterized as an endogenous molecule — its antimicrobial, immunomodulatory, and angiogenic activities are documented in numerous cell and animal studies, and it is a major topic in innate immunity and antimicrobial peptide research. What does not exist is an approval-grade clinical program establishing exogenous LL-37 as a safe, effective therapy for any wellness, infection, or healing indication. It is best understood as a heavily studied natural peptide and research tool, not a validated treatment.

• 37-amino-acid human cathelicidin from hCAP-18, produced by neutrophils and epithelial cells.
• Direct broad-spectrum antimicrobial action plus immunomodulatory and angiogenic (FPR2) signaling.
• Context-dependent / double-edged biology; no approval-grade therapeutic program.

Regulatory Status

The status below reflects mid-2026 and may change; verify before relying on it. LL-37 is not FDA-approved for any indication. It is sold as a research-grade compound for laboratory use only and, by its labeling, is not for human consumption. Given its context-dependent and potentially pro-inflammatory effects, casual framing as a benign “immune” or “antimicrobial” supplement would misrepresent the science.

Why LL-37 Draws Research Interest

LL-37 is a cornerstone of innate immunity and a fascinating multifunctional peptide of strong interest in antimicrobial resistance, immunomodulation, wound healing, and angiogenesis research, partly because endogenous antimicrobial peptides are seen as potential templates for new anti-infectives. The accurate framing is that it is a well-characterized natural host-defense peptide with genuine antimicrobial and signaling activities, important context-dependent (double-edged) biology, no approval-grade therapeutic evidence, and research-only status.

For deeper reading, the cited literature is the best starting point. For related host-defense and tissue peptides, see the KPV and BPC-157 overviews. The wider class is collected in our peptide research library.